Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib in Moderate to Severe Active Systemic Lupus Erythematosus
NCT02908100Phase 2Completed
- Sponsor
- Genentech
- Start
- Jan 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of fenebrutinib in systemic lupus erythematosus (SLE), sponsored by Genentech. Started Jan 2017; status: completed.
02
Drugs
fenebrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02908100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908100.